Apidra Injection, Solution
Product Images NDC 0088-2500

Product Visual Gallery

This gallery contains 40 technical images submitted to the FDA as part of the official labeling for Apidra (NDC 0088-2500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 01)

Line graph depicting glucose levels (mg/dL) over time (hours) comparing Apidra and Regular insulin before meals. The graph shows glucose concentration trends for Apidra (solid red line) and Regular insulin (dashed blue line) over a 7-hour period, illustrating their respective glucose-lowering profiles after administration.*

FDA Label Image

Figure 1b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 02)

A line graph labeled Figure 1B displaying glucose levels (mg/dL) over time (hours) comparing Apidra (insulin glulisine) and Regular insulin. The graph uses a solid red line for Apidra and a dashed blue line for Regular insulin, showing glucose reduction trends following administration.*

FDA Label Image

Figure 1c (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 03)

A line graph comparing blood glucose levels over time (hours) following injection for Apidra SoloStar (insulin glulisine) versus regular insulin. The graph uses a solid red line for Apidra post-injection data and a dashed blue line for regular insulin pre-injection data, with glucose levels in mg/dL on the y-axis and time on the x-axis.*

FDA Label Image

Figure (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 04)

An illustration showing an arrow labeled to indicate the start of a 15-minute meal, serving as a timing reference for meal-related activities.*

FDA Label Image

Figure 2 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 05)

A line graph comparing insulin levels (µIU/mL) over time (minutes) between insulin glulisine and regular insulin. The solid red line represents glulisine with a faster rise and peak around 60 minutes, while the dashed blue line shows regular insulin with a delayed and lower peak.*

FDA Label Image

Figure 3 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 06)

A pharmacokinetic curve comparing insulin levels (µIU/mL) over time (minutes) for two insulin types: glulisine and regular insulin. The graph shows glulisine insulin levels rising rapidly and peaking earlier than regular insulin, which has a slower, more prolonged profile.*

FDA Label Image

Figure 4 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 07)

A line graph comparing glucose infusion rates (GIR) in mg/kg/min over time (minutes) for three insulin types: Apidra (red solid line), Lispro (blue dotted line), and Regular insulin (green dashed line). The graph shows the onset, peak, and decline of insulin activity across a 600-minute period after administration.*

FDA Label Image

Step 1 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 08)

An instructional illustration showing a hand removing the cap from a vial, suggesting preparation of an injection. This image is related to the use of Apidra SoloStar, insulin glulisine injection, solution.*

FDA Label Image

Step 2 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 09)

A black and white line drawing illustrating hands removing a protective foil or seal from the top of a small vial, demonstrating a step in preparing a medication for use.*

FDA Label Image

Step 3 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 10)

Instructional illustrations showing steps for preparing an injection. The first image depicts a hand drawing solution into a syringe from a vial. The second image shows a hand attaching a needle cap or removing a needle cover from the syringe, indicating preparation for injection.*

FDA Label Image

Step 4 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 11)

An instructional illustration showing hands manipulating a syringe, with an arrow indicating a step in handling or preparing the injection device, likely related to Apidra SoloStar insulin glulisine injection preparation.*

FDA Label Image

Step 5 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 12)

An instructional diagram showing hands preparing an injection with a syringe and vial. One hand holds the vial upside down while the other hand pulls back the syringe plunger, withdrawing the liquid medication from the vial.*

FDA Label Image

Step 7 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 13)

An anatomical illustration highlighting recommended subcutaneous injection sites for Apidra SoloStar insulin glulisine injection. The labeled green areas include the upper arms, stomach, and thighs for injection placement.*

FDA Label Image

Step 7 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 14)

An instructional illustration showing a person's hands applying an adhesive bandage to the forearm, typically after an injection. The image emphasizes proper placement and securing of the bandage on the skin.*

FDA Label Image

Step 8 (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 15)

An instructional illustration depicting a hand holding a syringe and injecting into the side of a finger, commonly associated with a blood glucose test or insulin injection technique for subcutaneous administration.*

FDA Label Image

Figure (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 16)

An anatomical diagram showing recommended injection sites for subcutaneous administration. Areas highlighted in green include the upper arms, stomach, and thighs, indicating suitable locations for insulin glulisine injection.*

FDA Label Image

Figure (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 17)

An instructional diagram of the Apidra SoloStar insulin glulisine injection pen showing labeled parts including the pen cap, pen needle components (needle, inner and outer needle caps, protective seal), insulin reservoir with rubber seal, and the pen body featuring dose window, dosage selector, and injection button.*

FDA Label Image

Step 1a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 18)

Apidra SoloStar injection pen for subcutaneous use, containing insulin glulisine at 100 units/mL strength. The label states it is for single patient use only. The pen is manufactured by sanofi-aventis U.S. LLC.*

FDA Label Image

Step 1b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 19)

Illustration showing hands holding an Apidra SoloStar injector pen, demonstrating how to place and slide the pen cap onto the device. The image indicates the correct handling procedure for the insulin glulisine injection pen to ensure proper use and storage.*

FDA Label Image

Step 1c (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 20)

Apidra SoloStar insulin glulisine injection 100 units/mL (U-100) in a prefilled SoloStar pen for subcutaneous use. The image shows the dose window with graduated markings and the product label from sanofi-aventis U.S. LLC, indicating single patient use.*

FDA Label Image

Step 1d (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 21)

An illustration showing hands holding an Apidra SoloStar injection pen and removing the protective paper from the needle cap in preparation for subcutaneous injection. The image visually demonstrates part of the injection pen's setup before use.*

FDA Label Image

Step 2a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 22)

Black and white line drawing showing two hands removing a cap from a small cylindrical object, likely illustrating how to open or prepare an injection device or vial for Apidra SoloStar. The image focuses on hand positioning and cap removal.*

FDA Label Image

Step 2b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 23)

Instructional diagram illustrating the proper removal of the needle cap from the Apidra SoloStar insulin glulisine injection pen. The image shows hands twisting the needle cap off with directional arrows, including a caution symbol indicating not to pull the cap straight off.*

FDA Label Image

Step 2c (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 24)

Illustration showing the steps to use an Apidra SoloStar injection pen, including removing the cap from the insulin pen cartridge and preparing the pen for injection. The insulin pen is labeled with Apidra SoloStar and features a dosage scale.*

FDA Label Image

Step 2d (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 25)

An instructional illustration showing a hand holding a syringe and another hand removing or placing a cap on a container. The image depicts the action of opening or closing the container, with a blue arrow indicating the movement of the cap away from the container opening.*

FDA Label Image

Step 3a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 26)

An instructional illustration showing hands holding an Apidra SoloStar prefilled pen for subcutaneous injection. A close-up inset highlights the dose selector dial on the pen, indicating how to adjust the insulin glulisine dosage. The image demonstrates the correct method to turn the dial to set the dose before injection.*

FDA Label Image

Step 3b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 27)

An instructional diagram showing a person holding an Apidra SoloStar insulin injection pen. The image focuses on releasing air by pressing the injection button, with a close-up circle highlighting a drop emerging from the needle tip, indicating the expulsion of air or insulin solution from the pen.*

FDA Label Image

Step 4a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 28)

Apidra SoloStar 100 units/mL injection pen label, showing insulin glulisine solution for subcutaneous use. The label indicates single patient use only. The pen includes a dose window with a dial displaying dosage numbers, and a gray and blue exterior with a transparent section showing the dosage markings on the cartridge.*

FDA Label Image

Step 4b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 29)

An illustration showing how to remove the cap from an Apidra SoloStar insulin glulisine injection pen. The image depicts a hand gripping the pen and another hand lifting the cap upward, indicated by a blue arrow, demonstrating the step to prepare the pen for use.*

FDA Label Image

Figure (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 30)

An illustration showing a close-up of a dosing window on an insulin pen, highlighting dose numbers 10, 20, and 22 for injection measurement.*

FDA Label Image

Figure (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 31)

FDA Label Image

Step 5b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 32)

An instructional illustration showing a hand holding an Apidra SoloStar insulin glulisine injection pen. The image demonstrates the act of pressing the injection pen against the skin with an arrow indicating the injection direction for subcutaneous administration.*

FDA Label Image

Step 5c (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 33)

Instructional illustration showing correct and incorrect methods for holding the dose knob on the Apidra SoloStar insulin glulisine injection pen. The correct method involves turning the dose knob using the pad of the thumb, while the incorrect method shows twisting with the thumb curled over the knob.*

FDA Label Image

Step 5d (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 34)

An instructional illustration showing a hand holding an Apidra SoloStar pen injector in preparation for subcutaneous injection. A close-up inset indicates pressing the injection button and holding for 10 seconds to complete the dose delivery, demonstrating proper injection technique.*

FDA Label Image

Step 6a (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 35)

An instructional illustration showing hands holding an Apidra SoloStar insulin glulisine 100 units/mL injection pen. The image depicts the removal of the pen's needle cap, indicated by a blue arrow pointing away from the pen, guiding proper preparation for subcutaneous administration.*

FDA Label Image

Step 6b (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 36)

Illustration showing how to prime an Apidra SoloStar insulin glulisine injection pen. It depicts fingers holding the pen and twisting the dose knob while pressing the injection button, with arrows indicating the twisting and pressing actions on the subcutaneous injection device.*

FDA Label Image

Step 6c (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 37)

Illustration showing a hand removing a cap from a container while the other hand holds a small component, indicating the process of opening or accessing the container contents. The component appears to be intended for insertion into the container opening.*

FDA Label Image

Step 6d (E7af6a7a 8046 4fb4 9979 4ec4230b23aa 38)

An instructional illustration showing hands holding an Apidra SoloStar injection pen and removing the cap by pulling it off in the indicated direction, as part of the injection preparation process.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Carton packaging label for Apidra 100 units/mL (U-100) injection, containing insulin glulisine. The label indicates it is for subcutaneous use and intravenous infusion after further dilution under direct medical supervision. The package describes a 10 mL multiple-dose vial and provides storage instructions, warnings, manufacturer information (sanofi-aventis U.S. LLC), and batch details.*

FDA Label Image

Principal Display Panel (3 mL Pen Carton)

Packaging label for Apidra SoloStar insulin glulisine injection, 100 units/mL (U-100) solution, in a carton containing five 3 mL prefilled pens for subcutaneous use. The label highlights single patient use, clear and colorless solution, no included needles, and use within 28 days after initial use. Labeler is sanofi-aventis U.S. LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.